Christopher B. Morse

Christopher B. Morse

Auto-generated profile, based on publicly available information

Christopher B. Morse

15Obstetrics and Gynecology, Allegheny General Hospital, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2014 in Journal of Adolescent and Young Adult Oncology
Verified
Journal Article
Open access
NLNataniel H. Lester-Coll
Nataniel H. Lester-Coll
CMChristopher B. Morse
Christopher B. Morse
HZHuifang A. Zhai
Huifang A. Zhai
SBStefan Both
Stefan Both
JGJill P. Ginsberg
Jill P. Ginsberg
CHChristine E. Hill-Kayser
Christine E. Hill-Kayser
Craniospinal irradiation (CSI) is associated with infertility risk for adolescent/young adult women. We explore two methods of reducing ovarian exposure: oophoropexy (surgical removal of the ovaries from the path of the X-ray beam) and proton therapy (to allow the beam to stop without exposing the ovaries/uterus). In the case discussed, oophoropexy followed by X-ray CSI reduced ovarian dose to that at which 50% of oocytes are expected to survive, and the patient appears to have viable oocytes; this technique did not reduce uterine dose. Proton therapy would have eliminated the ovarian and uterine dose and the need for oophoropexy.

7 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
JLJung-Min Lee
Jung-Min Lee
AMAustin Miller
Austin Miller
PRPeter G. Rose
Peter G. Rose
MAMariam Alhilli
Mariam Alhilli
CWChristina Washington
Christina Washington
JLJoyce F. Liu
Joyce F. Liu
Purpose: We assessed the efficacy of anti–PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior bevacizumab. Patients and Methods: NRG-GY023 was the first randomized four-arm superiority phase II trial enrolling patients with high-grade serous/endometrioid or clear-cell PROC with prior bevacizumab exposure. Patients were randomized 1:2:2:2 to SOC (weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin), DOC, durvalumab + cediranib (DC), or olaparib + cediranib (OC). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, overall response rate, and safety. The design had 80% power to detect an HR of 0.5 using a one-sided, α = 0.1-level test for each comparison with the SOC with a preplanned interim analysis. Experimental arms with HR estimates (vs. SOC) >0.87 could be discontinued. Results: A total of 153 patients were enrolled between April 4, 2021, and February 1, 2023. Accrual was permanently closed on February 1, 2023, due to futility. With a data cutoff of September 9, 2024, the median PFS was 3.4, 2.9, 2.5, and 2.8 months, and median overall survival was 7.5, 8.3, 5.7, and 10.2 months for SOC, DOC, DC, and OC, respectively. The overall response rate was 4.3% [95% confidence interval (CI), 0.00–0.19], 15.9% (95% CI, 0.07–0.29), 11.9% (95% CI, 0.05–0.24), and 9.1% (95% CI, 0.03–0.20) for SOC, DOC, DC, and OC, respectively. Compared with SOC, the PFS HR estimates were 1.003 (95% CI, 0.56–1.80), 1.108 (95% CI, 0.63–1.96), and 1.021 (95% CI, 0.57–1.82) for DOC, DC, and OC, respectively. No new safety signals were observed. Conclusions: In patients with PROC with prior bevacizumab, all experimental arms failed to reach the primary objective of improving PFS compared with SOC.


13 June 2025
Verified
Other
Open access
JLJung-Min Lee
Jung-Min Lee
AMAustin Miller
Austin Miller
PRPeter G. Rose
Peter G. Rose
MAMariam Alhilli
Mariam Alhilli
CWChristina Washington
Christina Washington
JLJoyce F. Liu
Joyce F. Liu
Supplementary Table 3. Experimental Arm Hazard Ratio Estimates for interim analysis (N = 120)

13 June 2025
Verified
Other
Open access
JLJung-Min Lee
Jung-Min Lee
AMAustin Miller
Austin Miller
PRPeter G. Rose
Peter G. Rose
MAMariam Alhilli
Mariam Alhilli
CWChristina Washington
Christina Washington
JLJoyce F. Liu
Joyce F. Liu
Supplementary Figure 1. Progression-free survival and overall survival by randomized treatment (N = 120). Distributions were estimated utilizing the Kaplan-Meier method for progression-free survival (PFS) by investigator assessment. Hazard ratios (HR) are estimated with a proportional hazards model stratified by prior PARP inhibitor (yes vs no) and prior immune checkpoint inhibitor (yes vs no). The confidence intervals (CIs) are adjusted to provide 95% simultaneous coverage for the study’s original 4 treatment comparisons. The P-values are adjusted for multiple comparisons for PFS.

13 June 2025
Verified
Other
Open access
JLJung-Min Lee
Jung-Min Lee
AMAustin Miller
Austin Miller
PRPeter G. Rose
Peter G. Rose
MAMariam Alhilli
Mariam Alhilli
CWChristina Washington
Christina Washington
JLJoyce F. Liu
Joyce F. Liu
Purpose:We assessed the efficacy of anti–PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior bevacizumab.Patients and Methods:NRG-GY023 was the first randomized four-arm superiority phase II trial enrolling patients with high-grade serous/endometrioid or clear-cell PROC with prior bevacizumab exposure. Patients were randomized 1:2:2:2 to SOC (weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin), DOC, durvalumab + cediranib (DC), or olaparib + cediranib (OC). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, overall response rate, and safety. The design had 80% power to detect an HR of 0.5 using a one-sided, α = 0.1-level test for each comparison with the SOC with a preplanned interim analysis. Experimental arms with HR estimates (vs. SOC) >0.87 could be discontinued.Results:A total of 153 patients were enrolled between April 4, 2021, and February 1, 2023. Accrual was permanently closed on February 1, 2023, due to futility. With a data cutoff of September 9, 2024, the median PFS was 3.4, 2.9, 2.5, and 2.8 months, and median overall survival was 7.5, 8.3, 5.7, and 10.2 months for SOC, DOC, DC, and OC, respectively. The overall response rate was 4.3% [95% confidence interval (CI), 0.00–0.19], 15.9% (95% CI, 0.07–0.29), 11.9% (95% CI, 0.05–0.24), and 9.1% (95% CI, 0.03–0.20) for SOC, DOC, DC, and OC, respectively. Compared with SOC, the PFS HR estimates were 1.003 (95% CI, 0.56–1.80), 1.108 (95% CI, 0.63–1.96), and 1.021 (95% CI, 0.57–1.82) for DOC, DC, and OC, respectively. No new safety signals were observed.Conclusions:In patients with PROC with prior bevacizumab, all experimental arms failed to reach the primary objective of improving PFS compared with SOC.